20 DRUG DISCOVERY AND DEVELOPMENT
and global sales and marketing infrastructure.
It is one of the first joint ventures between a multinational pharmaceutical company and a local leading pharmaceutical company in branded generic medicines in China, and is also one of the largest pharmaceutical joint venture projects in Zhejiang province.
Fig. 1. EMD Millipore’s advanced GMP bioproduction facility in Martillac, France, offers users a full, single-use process train to speed a molecule’s journey to the clinic.
Collaboration helps cut drug development costs
As the cost and complexity of drug development continues to grow, collaboration between manufacturers is becoming an ever more important aspect of the business.
Etant donné que les frais et la complexité du développement de médicaments continuent d’augmenter, la collaboration entre les producteurs est en train de devenir un aspect de plus en plus important en affaires.
Da Kosten und Komplexität bei der Medikamentenentwicklung weiter zunehmen, wird die Zusammenarbeit unterschiedlicher Hersteller ein zunehmend wichtiger Faktor der Branche.
P
www.scientistlive.com
fizer, the world’s largest research-based pharmaceutical company, and
Zhejiang Hisun Pharmaceuticals have launched Hisun-Pfizer, a joint venture to develop, manufacture and commercialise off-patent pharmaceutical products in China and global markets.
Te creation of the joint venture marks an important milestone in strengthening the ability of both companies to reach more patients with high-quality and low-cost
medicines in the branded generics arena.
Off-patent medicines, including branded generics, represent one of the fastest-growing segments in the global pharmaceutical market. Tis is especially true in emerging markets, where cost and access are primary drivers of off-patent medicine growth. In China, branded generics account for 70 per cent of the domestic pharmaceutical market.
Hisun-Pfizer will take advantage of Hisun’s strong product portfolio, broad market outreach and experience with the production and commercialisation of branded generic medicines. Te joint venture will also benefit from Pfizer’s world class R&D, manufacturing quality management, international market promotion and operational capabilities. It will focus on R&D and the production and commercialisation of high-quality branded generic medicines, and the broader commercialisation of existing medicines through a local
Bai Hua, chairman and president of Hisun, said that establishing this joint venture with a leading global pharmaceutical company is an important step towards achieving Hisun’s long-term vision of becoming a widely respected international pharmaceutical company “persisting in pharmaceutical innovation for the benefit of human beings.”
Te partnership also paves the way for Hisun to transition from being an active pharmaceutical ingredients (API) manufacturer to an established branded generics company. “Te joint venture will provide our patients with high-quality and low-cost branded generic medicines through our internationally compatible management systems and R&D and production technology. Tis will help us better contribute to the development of the Chinese pharmaceutical industry, advance the drug innovation and manufacturing capabilities of Zhejiang province and China, and lay a solid foundation for Chinese pharmaceutical companies to enter the international market,” he said.
“Providing high-quality, accessible and affordable health care to people over a vast area and from broad socioeconomic levels has become a primary objective of Chinese healthcare reforms, which is aligned with Pfizer’s mission to provide high- quality and affordable medicines to our patients,” said Xiaobing Wu, country manager of Pfizer China. “Te joint venture demonstrates Pfizer’s commitment to China’s ongoing healthcare reforms and is an important milestone for Pfizer’s efforts to broaden the reach of its
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52